NAA10 Antibody – Mouse Polyclonal

N-alpha-acetylation is among the most common post-translational protein modifications in eukaryotic cells. This process involves the transfer of an acetyl group from acetyl-coenzyme A to the alpha-amino group on a nascent polypeptide and is essential for normal cell function. This gene encodes an N-terminal acetyltransferase that functions as the catalytic subunit of the major amino-terminal acetyltransferase A complex. Mutations in this gene are the cause of Ogden syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan 2012]

NAA10: In complex with NAA15, displays alpha (N-terminal) acetyltransferase activity. Without NAA15, displays epsilon (internal) acetyltransferase activity towards HIF1A, thereby promoting its degradation. Represses MYLK kinase activity by acetylation, and thus represses tumor cell migration. Interacts with HIF1A (via its ODD domain); the interaction increases HIF1A protein stability during normoxia, and down-regulates it when induced by hypoxia. Interacts with NAA15, NAA50 and with the ribosome. Binds to MYLK. Ubiquitous. Belongs to the acetyltransferase family. ARD1 subfamily.

Protein type: Amino Acid Metabolism - phenylalanine; Amino Acid Metabolism - tyrosine; Lipid Metabolism - glycerophospholipid; Acetyltransferase; Secondary Metabolites Metabolism - limonene and pinene degradation; EC 2.3.1.88

Chromosomal Location of Human Ortholog: Xq28

Cellular Component: membrane; cytoplasm; nucleolus; intracellular; nucleus

Molecular Function: peptide alpha-N-acetyltransferase activity; protein binding; N-acetyltransferase activity; acetyltransferase activity; ribosome binding

Biological Process: N-terminal protein amino acid acetylation; N-terminal peptidyl-glutamic acid acetylation; internal protein amino acid acetylation; N-terminal peptidyl-serine acetylation; DNA packaging

Disease: Ogden Syndrome; Microphthalmia, Syndromic 1